Our immunotherapeutic treatment based on anti-TERT CTLs infusion significantly controlled tumour growth inducing a survival benefit on treated mice compared to mice treated with hHCV1406-1415-specific TCR-engineered T-cells (Figure 2A-2B). The gene discussed is TERT; the disease is neoplasm.